Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline – In-depth Analysis into Clinical Trials, Emerging Drugs, and Treatment Outlook | Key Players – ITM Isotopen Technologien and EpicentRx

January 18 16:30 2022
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline - In-depth Analysis into Clinical Trials, Emerging Drugs, and Treatment Outlook | Key Players - ITM Isotopen Technologien and EpicentRx
Delveinsight Business Research LLP
“Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Market.

The Gastroenteropancreatic Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Download Sample Pages @ https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of GEP-NETs with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Gastroenteropancreatic Neuroendocrine Tumors Treatment.

  • GEP-NETs key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • GEP-NETs Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the GEP-NETs market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Landscape

Various Key players such as ITM Isotopen Technologien Muenchen (ITM), EpicentRx, and others are in the process of developing potential therapies for the treatment of Gastroenteropancreatic Neuroendocrine Tumour.

Gastroenteropancreatic Neuroendocrine Tumors Therapies covered in the report include:

  • RRx-001

  • CVM-1118

  • Solucin (n.c.a. 177Lu-Edotreotide / n.c.a. 177Lu-DOTATOC)

And many more.

The launch of emerging products will significantly impact the Gastroenteropancreatic Neuroendocrine Tumour market in the coming years.

Request for Sample Pages @ Gastroenteropancreatic Neuroendocrine Tumors Emerging Therapies and Key Companies

Table of Content

1. Report Introduction

2. Gastroenteropancreatic Neuroendocrine Tumors

3. Gastroenteropancreatic Neuroendocrine Tumors Current Treatment Patterns

4. Gastroenteropancreatic Neuroendocrine Tumors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Gastroenteropancreatic Neuroendocrine Tumors Late Stage Products (Phase-III)

7. Gastroenteropancreatic Neuroendocrine Tumors Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Gastroenteropancreatic Neuroendocrine Tumors Discontinued Products

13. Gastroenteropancreatic Neuroendocrine Tumors Product Profiles

14. Gastroenteropancreatic Neuroendocrine Tumors Key Companies

15. Gastroenteropancreatic Neuroendocrine Tumors Key Products

16. Dormant and Discontinued Products

17. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs

18. Gastroenteropancreatic Neuroendocrine Tumors Future Perspectives

19. Gastroenteropancreatic Neuroendocrine Tumors Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report: https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-pipeline-insight 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: